BPC-157 Gets Its First Human RCT — What It Tests (And What It Won't Answer)
THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Wednesday, March 4, 2026 | Issue #3
Data status: Third consecutive day of zero live search results across all 12 tracked metrics. Baseline pricing below is sourced from Q4 2025 research — treat every price range as a directional estimate, not a current quote. Verify with your vendor before ordering. I'll say this once and move on.
COMPOUND WATCH
Pricing vintage: Q4 2025 baseline — verify before ordering
BPC-157 Gray market: ~$25-60/vial [COA Only] | Compounder: ~$150-300/month [COA Only]
Evidence: [Phase 2] for hamstring repair (first human trial, recruiting now)
[Animal] for everything else your community is claiming
TB-500 Category 2, enforcement discretion only
No independent HPLC data this week
Evidence: [Animal]
CJC-1295 / Regulatory limbo — RFK intent announced, no formal rule
Ipamorelin Compounder access: restricted but not zero
Evidence: [Animal] / [Anecdotal]
Tirzepatide 503A/503B window still open as of today
(compounded) Compounder: ~$200-400/month [COA Only] | Brand Zepbound: ~$1,000+/month
Evidence: [Phase 3] — most evidence-backed compound your compounder stocks
Retatrutide Phase 3 recruiting (NCT07357415, started Jan 24, 2026)
Gray market supply exists — [Unverified], no independent HPLC confirmed
Evidence: [Phase 3] — watch this one; not yet compounded legitimately
The week's most important compound update: BPC-157 has a recruiting Phase 2 RCT (NCT07437547). The compound you're currently injecting based on [Animal] data alone is now being formally tested in humans for the first time. That's not validation — it's the beginning of actual evidence. Everything else in the peptide space this week is secondary.
Hims-Novo context for tirzepatide buyers: In March 2026, Hims & Hers announced a distribution partnership with Novo Nordisk — the reported structure moves Hims from independently compounding semaglutide to distributing Novo's authorized product. Deal terms remain unconfirmed. If other telehealth platforms follow this template, the 503A access point for GLP-1s narrows. If your compounder is showing tirzepatide out of stock, this pipeline disruption may be why. Call before you need a refill.
VENDOR SIGNAL
No fresh Finnrick rating changes, HPLC results, or Janoshik data today. Three consecutive days of silence. That's not a green light — it's a visibility gap.
[Verified]: No new vendors entered the verified pool this week. Check finnrick.com directly before your next order — ratings change without announcement, and three days of no data means three days of potential changes uncaptured here.
[COA Only]: The default state for most compounders and gray-market research vendors. A vendor-supplied COA is not independent verification. Approximately 15–20% of supplier COAs show discrepancies when tested by a third party — this figure is drawn from community HPLC testing aggregates compiled at Finnrick, not a single published study, and should be treated as a directional estimate rather than a precise rate. If your vendor can't name the independent lab that tested their batch, you have a [COA Only] at best.
[Flagged]: No new FDA warning letters or vendor shutdowns confirmed today.
The gray-market vs. compounder decision you're actually making: If you're choosing between QSC/SRY and a domestic compounder for BPC-157 right now, here's the cost-benefit as it stands. Gray-market Chinese supply carries two quantifiable risks: (1) tariff exposure — a sustained 25% tariff on Chinese goods could raise your per-vial cost 15–30% at the U.S. importer level, turning a $35 vial into $40–45 before margin adjustments; (2) customs seizure — community-reported estimates put gray-market peptide seizure rates at roughly 5–15% at current inspection volumes. That's not verified data; it's the community's working estimate. Factor both into your per-vial math. If your compounder is in stock, the markup is real but so is the supply chain certainty. If they're out of stock, that's a different calculation — and right now, the Hims-Novo pipeline disruption makes restock timing less predictable than it was 60 days ago.
TRIAL TRACKER
🔬 BPC-157 Phase 2 — Acute Hamstring Muscle Strain (NCT07437547) [Phase 2] | Recruiting | Started February 2, 2026
(NCT numbers are ClinicalTrials.gov registration IDs — paste any NCT number at clinicaltrials.gov to pull the full protocol.)
This is the one. After years of Croatian rodent studies and Reddit anecdote stacks, BPC-157 has its first registered human RCT. The indication is acute hamstring muscle strain — not systemic healing, not gut repair, not the laundry list of claims on r/peptides. This trial will answer one narrow question about one injury type. If it shows signal, it creates the scientific foundation for broader human trials. If it shows nothing, that's also data you should weight accordingly. The compound has zero published human RCTs before February 2, 2026. Now there's one recruiting. That's the most important change in the peptide evidence landscape this year.
🔬 Retatrutide Phase 3 — Obesity Without T2D (NCT07357415) [Phase 3] | Recruiting | Started January 24, 2026
Lilly's triple agonist (GIP/GLP-1/glucagon) is now in Phase 3 for obesity in non-diabetic patients. Phase 2 data showed up to 24.2% body weight reduction at 48 weeks. For comparison, tirzepatide's Phase 3 ceiling was approximately ~22.5% — but these figures come from different trial designs, different durations, and different patient populations. A 1.7 percentage point gap between two non-comparable trials is directionally interesting, not statistically definitive. No head-to-head data exists yet. Gray-market retatrutide is already circulating from Chinese suppliers — [Unverified], no independent HPLC confirmation in tracked data. If you're using it, you're running approximately two years ahead of the human evidence.
🔬 Survodutide Phase 3 — MASH/Cirrhosis (NCT06632457) [Phase 3] | Recruiting | Started November 2024
Boehringer Ingelheim's GLP-1/glucagon dual agonist in Phase 3 for liver disease. Worth tracking because the MASH/liver fibrosis population significantly overlaps with the metabolic dysfunction population already using GLP-1s for weight loss. Phase 2 data (NASH/MASH indication) showed ~6.1% improvement in liver stiffness and meaningful reductions in liver fat fraction at 24 weeks — enough to justify Phase 3, not enough to call it proven. Not actionable today. If Phase 3 reads out positive (likely 2027), this becomes a compound with a dual metabolic + liver indication that compounders will want access to. Gray-market supply exists; independent verification does not. [Unverified].
THE ODDS
Polymarket signals translated for your monthly spend. Real money, real signal.
Lead signal: Inflation at 80% probability of exceeding 3% in 2026 ($114,756 traded)
This is the most directly relevant signal to your budget. Pharmaceutical-grade excipients, sterile vials, and 503A pharmacy labor all track broader input cost inflation. At 80% probability of CPI above 3%, model a 5–15% compounding cost drift by Q3. On a $300/month peptide budget, that's $15–45/month in additional spend by fall — real money. The action isn't panic; it's timing. If you're considering locking in a longer-term compounder relationship or pre-purchasing supplies, the inflation trajectory argues for sooner over later.
China tariff signal: 2% probability of tariff relief by March 31 ($135,479 traded)
Near-zero probability of a tariff rebate means tariff pressure on Chinese goods is not going away. The gray-market peptide supply chain — BPC-157, TB-500, CJC-1295, and most GLP-1 analogs — runs through Chinese manufacturers. A sustained 25% tariff translates to 15–30% cost increases at the U.S. importer level before vendors adjust margins. That $35 vial becomes $40–45. No political relief mechanism is being priced in.
Recession signal: 32% probability of U.S. recession by end of 2026 ($515,394 traded — highest volume today)
32% is not a recession call. But watch the direction. If this drifts above 40% — a rule of thumb based on historical patterns where discretionary health spending compresses meaningfully at that threshold — the peptide market bifurcates: compounding pharmacy orders (the $300–500/month segment) decline as people cut discretionary spend, while gray-market orders (the $30–80/month DIY segment) increase as people seek cheaper alternatives. At 32%, you're not there yet. At 45%+, start thinking about whether your sourcing mix should shift toward gray-market to preserve access.
Fed rate signal: 23% probability of zero rate cuts in 2026 ($1,839,246 traded)
Less directly relevant to your vial cost, but watch the second-order effect: elevated rates increase capital costs for telehealth companies (Hims, Ro, Noom). The Hims-Novo authorized distribution deal may be partly a response to this — moving from a capital-intensive compounding model to a distribution model reduces balance sheet pressure. If other telehealth platforms follow, the 503A compounder access point for GLP-1s narrows further.
SIGNAL VS. NOISE
SIGNAL: BPC-157 Phase 2 RCT now recruiting (NCT07437547) Zero published human RCTs before February 2, 2026. Now one recruiting. Not validation — the start of actual evidence. This is structural, not hype.
SIGNAL: Retatrutide Phase 3 recruiting for non-diabetic obesity Phase 2 showed 24.2% weight reduction (different design than tirzepatide comparisons — see caveat above). Phase 3 is enrolling. Gray-market supply exists two years ahead of approval. [Unverified].
SIGNAL: 80% inflation probability → real compounding cost pressure by Q3 $15–45/month on a $300 budget. Model it now, not in September.
NOISE: Any claim that RFK's peptide reclassification is "done" No Federal Register notice published. No formal FDA rule issued. Enforcement discretion is not legality, and it can be withdrawn without notice. BPC-157, TB-500, CJC-1295, and Ipamorelin remain in regulatory limbo. Anyone telling you "it's fine now" is either uninformed or selling something.
NOISE: Gray-market retatrutide claims without independent testing Phase 3 is recruiting because the compound is promising — not because it's proven. No independent HPLC verification in tracked data. You may be injecting the right compound at the wrong dose, a related analog, or something else entirely. [Unverified] means [Unverified].
NOISE: Survodutide "available now" from research vendors Phase 3 trials ongoing. Not approved. Gray-market supply exists; independent verification does not. The liver disease indication makes this particularly high-stakes to get wrong.
REGULATORY RADAR
The RFK reclassification: still no formal rule
RFK Jr. announced HHS/FDA intent to reclassify approximately 14 of 19 Category 2 peptides back to Category 1 — which would reopen compounding access for BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, and others. That announcement generated enormous community excitement and a wave of "it's back" posts across r/peptides and Telegram.
The announcement is not a rule. No Federal Register notice has been published. No formal FDA guidance has been issued. The current legal status of these compounds has not changed. What exists is enforcement discretion — FDA may choose not to enforce against compounders producing these compounds, but that discretion can be withdrawn at any time, applied inconsistently, or challenged in court by a pharmaceutical company with standing.
On the practical enforcement risk: FDA is not currently running visible active enforcement campaigns against 503A compounders producing BPC-157 under enforcement discretion — but "not currently visible" is not the same as "safe." The risk is asymmetric: a single enforcement action against your compounder disrupts your supply chain immediately. Ask your compounder directly: What is your legal basis for production? If the answer is "RFK said it's okay," that is not a legal basis. A legitimate answer references specific FDA guidance documents or 503A statutory authority.
The Hims-Novo deal (announced March 2026, deal structure unconfirmed as of today) is the other story to watch. If it establishes a template where telehealth companies become authorized distributors rather than compounding competitors, the 503A/503B distinction becomes less relevant for GLP-1s — and the access point for compounded tirzepatide and semaglutide narrows. No confirmed deal terms. Watch for structural details.
No new FDA warning letters or enforcement actions confirmed today. Data gap, not a clean bill of health.
WHAT TO WATCH
Specific actions, not vague monitoring:
- BPC-157 Phase 2 (NCT07437547) — enrollment pace: Pull the trial record at ClinicalTrials.gov in 30 days. If enrollment is tracking ahead of schedule, that signals institutional interest in the compound beyond the trial sponsor. If it's slow, that's also data.
- Your compounder's tirzepatide restock timeline: Call this week — not when you're three days from running out. The Hims-Novo pipeline disruption is creating uncertainty that wasn't there 60 days ago. Get a restock date in writing if you can.
- Finnrick ratings: Check finnrick.com directly before any gray-market order. Three days without rating data means three days of potential changes uncaptured here.
- Federal Register: This is the document that actually changes the legal landscape for BPC-157, TB-500, and CJC-1295. Not published as of today. When it is, it will appear at federalregister.gov — search "503A bulks" or the specific compound name. That publication date is when the regulatory status actually changes, not before.
- Recession odds drift: Currently 32%. If Polymarket moves above 40%, revisit your compounder-vs.-gray-market sourcing mix. That's the threshold where historical discretionary health spending compression becomes meaningful — not a precise rule, but a useful trigger for reassessment.
Glossary for new readers: - [COA Only] = vendor-supplied certificate of analysis, not independently verified - [Verified] = independent HPLC confirmation, 98%+ purity - 503A = traditional compounding pharmacy (patient-specific prescriptions) - 503B = outsourcing facility (bulk production, higher regulatory bar)
The number that anchors this week: 0 — published human RCTs for BPC-157 before February 2, 2026. Now there's 1 recruiting. Everything else in the peptide evidence landscape this week is downstream of that fact.
Reply to this email with feedback — sourcing questions, evidence challenges, compounds you want graded. This newsletter gets better when you push back.
Stay curious, stay skeptical. — The Dose